News

All news CSR Events General PERSONAL CARE Press release Products & Technologies Protéus

SEQENS has announced it has reached an agreement in principle on a comprehensive financial restructuring

SEQENS has announced it has reached an agreement in principle on a comprehensive financial restructuring to strengthen its balance sheet and support its long-term strategy.

CELLforCURE launches a process to find a buyer for its Les Ulis site

SEQENS to launch PeptiCode™ HP-9: the first European biotech Hexapeptide-9

Sale of our Limoges Botanical Actives and In Vitro Diagnostics activities to Solabia

SEQENS new antiwear additive ROSCAN® 6253NV is registered on the LUSC list.

Pharma

Brenntag and SEQENS partner for the commercialization of non-GMP pharmaceutical intermediates in Europe

BBG Advanced Therapies and CELLforCURE partner to provide transatlantic manufacturing solutions for ATMPs

CELLforCURE by SEQENS to Manufacture Galapagos’ CAR T-Cell Therapy Candidates for Upcoming Trials

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

SEQENS and Novonesis announce strategic partnership for enhancing customer’s access to industrial biocatalytic processes

SEQENS announces the appointement of a new CEO

SEQENS and APPLEXION announce strategic partnership for the distribution of SEQENZYM FT

Smart Immune and CELLforCURE by SEQENS partner to industrialize SMART101 clinical batches manufacturing

1 2 3